Home » Cephalon Drug Prompts Response in Cancer Study
Cephalon Drug Prompts Response in Cancer Study
Biotechnology company Cephalon Inc. said its leukemia drug Treanda, in combination with Genentech Inc.'s Rituxan, prompted a response in non-Hodgkin's lymphoma patients during a midstage study.
Boston.com
Boston.com
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May